TITLE PAGE

NON-INTERVENTIONAL RESEARCHCLINICAL STUDY

PROTOCOL PROC-521-0124

A Prospective, Multicenter, Open-Label, Single-Arm, Post Marketing Observational Study to Assess the Effectiveness and Safety of Prochlorperazine In Patients with Acute Vertigo

Product Name: Stemetil MD®(prochlorperazine maleate 5 mg)

Type of Study:	Post-marketing Observational Study (PMOS)	
Protocol Version & Date:	Version 1.0 dated 22-Nov-2021	
CRO & Biometrics:	iDD Research Solutions Pvt. Ltd. Tek Meadows Campus, No 51, 3rd, C block, Old Mahabalipuram Rd, Sholinganallur, Chennai, Tamil Nadu 600119	Phone: +91 8520082152
Sponsor:	Abbott Healthcare Pvt. Limited Floor 16, Godrej BKC Plot No. C – 68, BKC Near MCA Club, Bandra (E) Mumbai 400 051	Phone: +91-22-38160619

This study will be conducted in compliance with this protocol.

Confidential Information

No use or disclosure outside Abbott is permitted without prior written authorization from Abbott.

SIGNATURE PAGE

INVESTIGATOR'S DECLARATION

I, the undersigned, have read and understood this protocol and hereby agree to conduct the study in accordance with this protocol and to comply with all requirements regarding the obligations of Investigators and all other Subject requirements of ICH-E6 R2 Guideline 2016 on 'Good Clinical Practice', New Drugs and Clinical Trials 2019, Declaration of Helsinki (Taipei 2016) and any other applicable regulations.

I further agree to ensure that all associates assisting in the conduct of study are informed regarding their obligations.

PRINCIPAL INVESTIGATOR

Signature Professor & Head, Department of E.N.T., A.C.P.M.Medical College, Dhule [M.S.] **Date (08-12-2022)**

Name : Dr. R.V.Patil

Address :

Telephone : +91

Email :

A.C.P.M. MEDICAL COLLEGE & HOSPITAL ★ DHULE ★